Review
Oncology
Amandine Badie, Christian Gaiddon, Georg Mellitzer
Summary: Our understanding of the identity of many cancers has greatly increased in recent years, leading to progress in early detection and treatment options. However, gastric cancer remains poorly treated with low survival rates. The lack of possibilities for early detection and the variations between tumors of gastric cancer patients are major challenges. Histone Deacetylases (HDACs) have been identified to be potentially related to gastric cancer. In this review, we summarize the current knowledge on the role of HDACs in gastric cancer development and their potential as early detection markers and targets for new treatment options.
Review
Oncology
Anna Wawruszak, Lidia Borkiewicz, Estera Okon, Wirginia Kukula-Koch, Syeda Afshan, Marta Halasa
Summary: Breast cancer remains a challenging malignancy with varying responses to therapy, requiring the development of new active agents to improve the current treatment regimens. Vorinostat (SAHA) shows promise in the therapy of different histological subtypes of breast cancer, either alone or in combination with other anticancer agents, based on preclinical and clinical trials data.
Article
Chemistry, Medicinal
Nils Goehringer, Yayi Peng, Bianca Nitzsche, Hannah Biermann, Rohan Pradhan, Rainer Schobert, Marco Herling, Michael Hoepfner, Bernhard Biersack
Summary: The development of new anticancer drugs is essential due to the limitations of current drugs. Histone deacetylases (HDACs) have emerged as promising targets for cancer treatment. SF5-SAHA, a newly synthesized HDAC inhibitor, showed strong inhibition of tumor cell growth and potential for further development as an anticancer drug candidate.
Article
Oncology
Weiyu Dai, Side Liu, Jieming Zhang, Miaomiao Pei, Yizhi Xiao, Jiaying Li, Linjie Hong, Jianjiao Lin, Jing Wang, Xiaosheng Wu, Guangnan Liu, Yaying Chen, Yusi Wang, Zhizhao Lin, Qiong Yang, Fachao Zhi, Guoxin Li, Weimei Tang, Aimin Li, Li Xiang, Jide Wang
Summary: miR-769-5p/miR-769-3p acts as a tumor suppressor in gastric cancer by targeting IGF1R and through the STAT3-IGF1R-HDAC3 complex. Treatment with the HDAC inhibitor SAHA triggers the expression of miR-769-5p/miR-769-3p, leading to inhibition of proliferation and induction of apoptosis in gastric cancer cells.
Article
Engineering, Environmental
Jian-Li Chen, Xiao-Hui Jia, Xinyue Xia, Xuan Wu, Yan-Neng Xu, Gang Yuan, Ze-Yun Gu, Kathy Qian Luo, Ming-Heng Yuan, Ruibin Jiang, Jianfang Wang, Xiao-Ming Zhu
Summary: In this study, hollow ZrO2 nanoshells were synthesized to encapsulate both the autophagy inhibitor chloroquine (CQ) and the HDAC inhibitor vorinostat (Vor) for effective combinational cancer therapy. The ZrO2 nanoshells showed high loading capacities for both CQ and Vor and exhibited a controlled release profile. The codelivery system enhanced the autophagy inhibition and hyperacetylation level in the cells, resulting in a superior antitumor effect in 4T1 tumor-bearing mice.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Zachary A. Bordeaux, Sriya V. Reddy, Kevin Lee, Weiying Lu, Justin Choi, Meghan Miller, Callie Roberts, Anthony Pollizzi, Shawn G. Kwatra, Madan M. Kwatra
Summary: This study investigates the molecular mechanism of vorinostat treatment in MF using transcriptomic and proteomic analysis. The results show that vorinostat downregulates CTLA-4, CXCR4, and CCR7 in both Myla 2059 and HH cell lines, but its effect on key signaling pathways differs between the two lines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Hae Jin Kee, Inkyeom Kim, Myung Ho Jeong
Summary: This article provides an overview of the pathogenesis of hypertension, current anti-hypertensive drugs, and the need for novel drugs. It focuses on the role and regulatory mechanisms of HDACs in hypertension and discusses the progress in developing HDAC inhibitors as potential therapeutic targets.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Dermatology
Liat Samuelov, Ron Bochner, Lee Magal, Kiril Malovitski, Nadav Sagiv, Janna Nousbeck, Aviad Keren, Dana Fuchs-Telem, Ofer Sarig, Amos Gilhar, Eli Sprecher
Summary: The study showed that the histone deacetylase inhibitor Vorinostat can effectively inhibit hyperproliferation of keratinocytes and induce their differentiation and apoptosis. In a chimeric mouse model, Vorinostat demonstrated significant improvement in psoriasis-like symptoms, indicating its potential use in treating psoriasis and other hyperproliferative skin disorders.
EXPERIMENTAL DERMATOLOGY
(2022)
Review
Oncology
Fengyi Guo, Hongjing Wang
Summary: This review summarizes the classification and mechanisms of action of histone deacetylase and the clinical application of their inhibitors in ovarian cancer. Histone deacetylase inhibitors show promising potential as anti-cancer drugs, and combination therapy with other anticancer drugs for synergistic effects can improve efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yang Yang, Yu Yan, Zhen Chen, Jie Hu, Kai Wang, Ni Tang, Xiaosong Li, Zhi Zhou
Summary: The study concluded that FK228 and SAHA treatment significantly promoted HBV replication and biosynthesis by inducing cell cycle arrest through regulating the expression of cell cycle regulatory proteins. Additionally, simultaneous inhibition of HDAC1/2 by FK228 was more effective in promoting HBV replication than the broad spectrum HDAC inhibitor SAHA.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Pharmacology & Pharmacy
Fengkun Lu, Lei Hou, Sizhen Wang, Yingjie Yu, Yunchang Zhang, Linhong Sun, Chen Wang, Zhiqiang Ma, Feng Yang
Summary: Studies have shown that the combination of epigenetic therapy and PD-1/PD-L1 blockade therapy can reverse immune escape, while lysosome activable polymeric vorinostat encapsulating PD-L1KD for the combination therapy of PD-L1-KD and HDACIs is an effective strategy to activate the immune system, inhibit tumor growth, and metastasis.
Article
Pharmacology & Pharmacy
Yingjie Yu, Bingkai Wang, Miao Sun, Yunchang Zhang, Lei Hou, Sizhen Wang, Tianheng Chen, Feng Yang, Zhiqiang Ma
Summary: Photothermal therapy (PTT) is widely used in clinical cancer treatment, but resistance and metastasis remain challenges. This study proposes that supplementing PTT with histone deacetylase acetylase inhibitor (HDACis) can overcome these obstacles. By fabricating a nano-complex, tumor growth can be effectively inhibited and thermotolerance and metastasis can be reversed during PTT.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Review
Oncology
Jason Lin, Shang-Chuen Wu
Summary: This review examines the role of protein serotonylation in transcriptional regulation, its potential impact on the epigenetic landscape, and its implications in lung and other types of cancer. The review discusses the mechanistic details of serotonylation and its connections to the epigenome, as well as the role of transglutaminase 2, in order to guide the development of optimized histone deacetylase inhibitor designs or combination therapies for cancer treatment.
Review
Cell Biology
Bingyi Zhou, Deliang Liu, Yuyong Tan
Summary: Cancer is the second leading cause of death worldwide, with digestive system cancers being a primary contributor. Acetylation and deacetylation play crucial roles in cancer development, with HDAC6 being a widely studied enzyme that is upregulated in various tumors and associated with clinicopathological characteristics. There is ongoing research on HDAC6 inhibitors and their potential in inhibiting tumor growth.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Svetlana Demyanenko, Valentina Dzreyan, Svetlana Sharifulina
Summary: Cerebral ischemia is the second leading cause of death worldwide, requiring multimodal stroke therapy. Histone deacetylase inhibitors have shown to be effective in protecting the brain from ischemic damage by inducing neurogenesis and angiogenesis in damaged brain areas, promoting functional recovery after stroke.